Pulmatrix Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ted Raad

Chief Executive Officer (CEO)

US$691.9k

Compensación total

Porcentaje del salario del CEO	82.0%
Permanencia del CEO	5yrs
Participación del CEO	n/a
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Jul 12

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Feb 22

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Oct 29

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Aug 16

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 14

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

May 27

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Feb 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ted Raad en comparación con los beneficios de Pulmatrix?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$692k	US$567k	-US$14m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$1m	US$525k	-US$19m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$1m	US$480k	-US$23m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$2m	US$464k	-US$19m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	US$823k	US$411k	-US$21m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$20m
Dec 31 2018	US$707k	US$345k	-US$21m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$20m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$963k	US$216k	-US$18m

Compensación vs. Mercado: La compensación total ($USD691.89K) de Ted está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Ted ha sido consistente con los resultados de la empresa en el último año.

CEO

Ted Raad (53 yo)

5yrs

Permanencia

US$691,888

Compensación

Mr. Teofilo David Raad, also known as Ted, MBA, has been Director at Oxeia Biopharmaceuticals Inc. since 2021. Mr. Raad serves as Chief Executive Officer, President and Director at Pulmatrix, Inc. since Ma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Teofilo Raad	President	5yrs	US$691.89k	sin datos
Peter Ludlum	Interim CFO and Principal Accounting & Financial Officer	2.1yrs	US$510.22k	sin datos
Alexander Klibanov	Founder	21.3yrs	sin datos	sin datos

5.0yrs

Permanencia media

68yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PULM es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Teofilo Raad	President	5yrs	US$691.89k	sin datos
Michael Higgins	Independent Chairman	8.9yrs	US$92.97k	0% $ 0
David Denning	Member of Pulmazole Clinical Advisory Board	no data	sin datos	sin datos
Christopher Cabell	Independent Director	3.9yrs	US$50.56k	0% $ 0
Jonathan Corren	Member of Pulmazole Clinical Advisory Board	no data	sin datos	sin datos
Richard Batycky	Independent Director	4.5yrs	US$59.56k	0.00068% $ 48.7
Todd Bazemore	Independent Director	3.6yrs	US$58.06k	0% $ 0
Ritesh Agarwal	Member of Pulmazole Clinical Advisory Board	no data	sin datos	sin datos
Cendrine Godet	Member of Pulmazole Clinical Advisory Board	no data	sin datos	sin datos
David Stevens	Member of Pulmazole Clinical Advisory Board	no data	sin datos	sin datos
William Calhoun	Chair of PUR1900 & PUR1800 Clinical Advisory Board	no data	sin datos	sin datos
Stephen Silberstein	Chair of PUR3100 (DHE) Clinical Advisory Board	no data	sin datos	sin datos

4.5yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de PULM se considera experimentada (4.4 años de antigüedad promedio).

Pulmatrix Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Recent updates

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$10.00

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad